Galmed Pharmaceuticals
GLMD
34 hedge funds and large institutions have $50.9M invested in Galmed Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 3 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 10
0.01% more ownership
Funds ownership: 0.2% → 0.2% (+0.01%)
0% more funds holding
Funds holding: 34 → 34 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
16% less capital invested
Capital invested by funds: $60.6M → $50.9M (-$9.66M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $74K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
II
Ibex Investors
Denver,
Colorado
|
+$1.06M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$605K |
| 3 |
PAM
Premier Asset Management
Chicago,
Illinois
|
+$558K |
| 4 |
RCG
Rock Creek Group
Washington,
District of Columbia
|
+$410K |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$191K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$330K |
| 2 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
-$143K |
| 3 |
Goldman Sachs
New York
|
-$138K |
| 4 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$103K |
| 5 |
FMBTD
First Midwest Bank Trust Division
Joliet,
Illinois
|
-$95.4K |
GLMD Hedge Fund Activity: Q2 2019 in Review
34 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q2 2019, worth a combined $50.9M — down 16% from $60.6M a quarter earlier.
Fund positioning in GLMD was balanced in Q2 2019: 3 funds opened new positions, 3 closed out, 12 added to existing stakes and 10 trimmed.
The largest buyer was Ibex Investors, adding an estimated $1.06M. The largest seller was BVF Inc, cutting an estimated $330K.
- 34 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q2 2019, unchanged from Q1 2019.
- Funds reported $50.9M of Galmed Pharmaceuticals stock for Q2 2019, down 16% quarter-over-quarter.
- 3 funds opened new Galmed Pharmaceuticals positions in Q2 2019 and 3 closed out, a net change of 0 holders.
- The largest Galmed Pharmaceuticals buyer in Q2 2019 was Ibex Investors, an estimated $1.06M added.
- The largest Galmed Pharmaceuticals seller in Q2 2019 was BVF Inc, an estimated $330K sold.
Based on aggregated 13F filings for Q2 2019.